Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,038.00
Bid: 12,038.00
Ask: 12,040.00
Change: 14.00 (0.12%)
Spread: 2.00 (0.017%)
Open: 11,950.00
High: 12,066.00
Low: 11,944.00
Prev. Close: 12,024.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-French health body approves AstraZeneca COVID-19 vaccine

Tue, 02nd Feb 2021 16:53

* Recommends use for those only aged under 65

* Decision makes AZ's vaccine third shot available in the
country
(Adds quote, details)

By Sudip Kar-Gupta and Geert De Clercq

PARIS, Feb 2 (Reuters) - France's top health advisory body
on Tuesday approved the use of AstraZeneca's COVID-19
vaccine, but said the shot should only be administered to those
aged under 65.

The Haute Autorite de la Sante (HAS) said people aged 50 to
65 with health issues and medical staff should get priority
access.

The decision makes AstraZeneca's vaccine the third shot
available in France, after those of Pfizer/BioNTech
and Moderna.

Its recommended use for those aged below 65 echoes similar
advice from experts in Italy, Austria, and Germany, which said
the vaccine should not be given to the elderly, citing a lack of
sufficient data to recommend use in older age groups.

"There is still insufficient data for those aged 65+. We
hope to have them in the coming weeks," the head of the HAS,
Dominique Le Guludec, told reporters.

"The vaccine's performance is satisfactory with a 62%-70%
efficacy depending on various study outcomes", she added.

The European Medicines Agency (EMA) gave the green light to
the AstraZeneca vaccine four days ago, saying there was not yet
enough results for people over the age of 55 to determine how
well the vaccine worked in that group but that it could still be
given to older people.

The approval is expected to ease pressure on the French
government, whose vaccination rollout strategy has been heavily
criticized for being too slow.

As of Feb. 1, more than 1.6 million doses had been
administered in France. That compares with an estimate of nearly
10 million in Britain.

But the European Union, which last year agreed to buy up to
400 million doses of the vaccine for the bloc, is at the centre
of a dispute with AstraZeneca over the speed of supplies.

Last week, the company unexpectedly announced cuts of up to
60% in supplies to European countries, citing production
problems at a Belgian factory and triggering a furious response
from Brussels.

The HAS said it expected France to get 10 million doses of
the AstraZeneca vaccine in the next three months, which would
allow 5 million people to get vaccinated, given its two-dose
regimen.

In the same timeframe, France hopes to secure 19.3 million
shots from Pfizer/BioNTech and 3 million from Moderna.

French European Affairs Minister Clement Beaune said on
Monday he expected first doses of the AstraZeneca vaccine to
arrive by next week at the latest.

(Reporting by Sudip Kar-Gupta, Geert De Clercq; Writing by
Matthias Blamont; Editing by Bernadette Baum and Rosalba
O'Brien)

More News
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.